Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuTPO versus rHuIL-11 for chemotherapy-induced thrombocytopenia in NSCLC
ChiCTR-TNC-10000758Phase 4Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- Feb 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin and oprelvekin in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Time to platelet recovery to at least 75 × 10^9/L and 100 × 10^9/L, Number and volume of platelet transfusions and 3 more. Started Feb 2010; status: completed.
02
Drugs
recombinant human thrombopoietinoprelvekin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR-TNC-10000758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000758.